Our study has potential clinical significance, because it may be beneficial for the use of medications such as metformin and GLP-1 receptor agonists in T2DM patients receiving insulin therapy, which can be regarded as insulin sensitisers and insulin sparing drugs to reduce the risk of atherosclerotic lesions and its complications. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.